pharma · Atopic Dermatitis · COVID-19
Qilu Pharmaceutical (Hainan) Co.,
Qilu Pharmaceuticals drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 4 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Qilu Pharmaceuticals drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Antiinfectives for systemic use (J07) compound in Qilu Pharmaceuticals's portfolio. Mechanism: Biological vaccine - induces immune response.
Development asset linked to Qilu Pharmaceuticals in public FDA and regional records.
Development asset linked to Qilu Pharmaceuticals in public FDA and regional records.
US regulatory status: approved. Molecular target: Cytochrome P450 3A.